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Acute Bronchitis
Richard P. Wenzel, M.D., and Alpha A. Fowler III, M.D.
This Journal feature begins with a case vignette highlighting a common clinical problem.
Evidence supporting various strategies is then presented, followed by a review of formal guidelines,
when they exist. The article ends with the authors’ clinical recommendations.

A 40-year-old man with no underlying lung disease has a 7-day history of mild shortness
of breath with exertion, as well as cough that is now productive of purulent sputum.
He reports no paroxysms of cough and no contact with ill persons in his community.
He does not appear to be in distress. His temperature is 37°C, his pulse 84 beats per
minute, and his respiratory rate 17 breaths per minute. On auscultation of the lungs,
no rales are heard; scattered wheezes are heard in the lung bases. How should he be
evaluated and treated?

The Cl inic a l Probl e m
Acute bronchitis is a clinical term implying a self-limited inflammation of the large
airways of the lung that is characterized by cough without pneumonia. The disorder
affects approximately 5% of adults annually,1,2 with a higher incidence observed during the winter and fall than in the summer and spring. In the United States, acute
bronchitis is the ninth most common illness among outpatients, as reported by physicians.3
Viruses are usually considered the cause of acute bronchitis but have been isolated
in a minority of patients.1,4 Those isolated in acute bronchitis (from the most to the
least common in large series) include influenza A and B viruses, parainfluenza virus,
respiratory syncytial virus, coronavirus, adenovirus, and rhinovirus. Human metapneumovirus has been identified as a causative agent.5-7 A recent French study involving adults who had been vaccinated against influenza showed a viral cause in 37%
of 164 cases of acute bronchitis, of which 21% were rhinovirus.4 Thus, the yield of
specific pathogens varies according to several factors, including the presence or absence of an epidemic, the season of the year, and the influenza vaccination status of
the population.
Bacterial species commonly implicated in community-acquired pneumonias are
isolated from the sputum in a minority of patients with acute bronchitis.1 However,
the role of these species in the disease or its attendant symptoms remains unclear,
because bronchial biopsies have not shown bacterial invasion. In some cases, atypical bacteria are important causes, including Bordetella pertussis, Chlamydophila (Chlamydia)
pneumoniae, and Mycoplasma pneumoniae.1 Some data have suggested that B. pertussis
may underlie 13 to 32% of cases of cough lasting 6 days or longer, although in a recent
prospective study, B. pertussis comprised only 1% of cases of acute bronchitis.8

From the Department of Internal Medicine, Virginia Commonwealth University,
Richmond. Address reprint requests to
Dr. Wenzel at the Department of Internal
Medicine, Virginia Commonwealth University, 1101 E. Broad St., P.O. Box 980663,
Richmond, VA 23298, or at rwenzel@
mcvh-vcu.edu.
N Engl J Med 2006;355:2125-30.
Copyright © 2006 Massachusetts Medical Society.

Pathobiology

Acute bronchitis is thought to reflect an inflammatory response to infections of the
epithelium of the bronchi. Epithelial-cell desquamation and denuding of the airway
to the level of the basement membrane in association with the presence of a lymphocytic cellular infiltrate have been demonstrated after influenza A tracheobronchitis9;
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microscopical examination has shown thickening
of the bronchial and tracheal mucosa corresponding to the inflamed areas. Such pathological
findings are consistent with reports of proximal
lower airway inflammation confined to the bronchi, as detected by positron-emission tomography
with 18F-fluorodeoxyglucose as a tracer, in the
setting of acute bronchitis.10
However, there are wide variations in the anatomical distribution of many pathogens that cause
acute bronchitis. In a study involving volunteers
exposed to rhinovirus infections, for example,
virus was detected in specimens of induced sputum obtained from all the subjects, in approximately one third of bronchial biopsy specimens,
in almost a quarter of bronchoalveolar lavage
specimens, and in more than a third of bronchial
brushing specimens.11 Such data indicating viral
infection of the lower airways may help to explain
the relationship observed between rhinovirus infection (and other presumed upper respiratory
viral infections) and exacerbation of asthma.12
Thus, although its name suggests only large-airway disease, acute bronchitis may be accompanied
by an array of symptoms, depending on the degree of viral involvement of the large and small
airways.
Natural History

During the first few days of infection, the symptoms of mild upper respiratory infections cannot
be distinguished from those of acute bronchitis.
However, with acute bronchitis, coughing persists
for more than 5 days, and during this protracted
period the results of pulmonary function testing
may become abnormal. Forty percent of patients
have significant reductions in the forced expiratory volume in 1 second (i.e., a value below 80% of
the predicted value)13 or bronchial hyperreactivity,
as measured by bronchial provocation,14 with improvement during the following 5 to 6 weeks.
Cough after acute bronchitis typically persists
for 10 to 20 days but occasionally may last for 4 or
more weeks. In a recent report on a clinical trial
of the efficacy of an acellular pertussis vaccine involving 2781 healthy adults, the median duration
of cough from acute bronchitis due to all causes
was 18 days (mean, 24).8 In addition, approximately 50% of patients with acute bronchitis report
the production of purulent sputum. In otherwise
healthy patients, purulent sputum usually indicates the presence of sloughed tracheobronchial
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epithelium and inflammatory cells, and its positive predictive value for the presence of alveolar
disease is low (approximately 10%).15
A study of the quality of life of patients with
upper respiratory tract infections, some of whom
had received a diagnosis of acute bronchitis,
showed significant decrements in seven subscales
of the Medical Outcomes Study 36-item ShortForm General Health Survey, including vitality and
social functioning,16 but such decrements are presumed to be transient. Data on short- or long-term
outcomes are limited, but one study indicated that
within a month after the initial visit, up to 20%
of patients had reconsulted their physicians because of persistent or recurrent symptoms.1 The
effect of an episode of acute bronchitis on a patient’s subsequent lung health is uncertain. In one
study, 34% of patients with acute bronchitis received a new diagnosis of chronic bronchitis or
asthma at 3 years of follow-up.17 In another study,
mild bronchial asthma was diagnosed on the basis
of spirometry or bronchial provocation in 65% of
patients with recurrent episodes of acute bronchitis.18 However, these studies lacked control groups,
and it is unclear whether acute bronchitis led directly to the chronic condition or whether the
chronic disorder or the propensity for its development was present at the time of the inflammation of the large airway.

S t r ategie s a nd E v idence
Diagnosis

Acute bronchitis should be differentiated from
acute inflammation of the small airways — asthma or bronchiolitis — which typically presents as
progressive cough accompanied by wheezing,
tachypnea, respiratory distress, and hypoxemia.
It should also be distinguished from bronchiectasis,19 a distinct phenomenon associated with permanent dilatation of bronchi and chronic cough.
The diagnosis of chronic bronchitis is reserved
for patients who have cough and sputum production on most days of the month for at least 3 months
of the year during 2 consecutive years.20 The acute
exacerbation of chronic bronchitis, identified by
the worsening air flow and symptoms in such patients, is not discussed here.
A careful history taking, including reports of
contact with ill people, and physical examination
may suggest a specific cause (Table 1). A common
presentation of pertussis is cough of 2 to 3 weeks’
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Table 1. Recognized Causes of Acute Bronchitis and Options for Therapy.*
Pathogen

Comments†

Options for Therapy

Influenza virus

Precipitous onset with fever, chills, headache, and
cough. Myalgias are common and may be accompanied by myositis, myoglobinuria, and
elevated serum levels of muscle enzymes.

Parainfluenzavirus

Epidemics may occur in autumn. Outbreaks may
occur in nursing homes. Croup in a child at
home suggests the presence of the organism.
Family history is important: approximately 45%
of family members exposed to an infant (≤1 yr
of age) with bronchiolitis become infected.22
Outbreaks occur in winter or spring. Twenty
percent of adults have ear pain.23
Pathogen can cause severe respiratory symptoms
in elderly patients. Epidemics of strain 0C43
with high attack rates have been reported
among military recruits.24
Infection is clinically similar to influenza, with
abrupt onset with fever.
Fever is uncommon, and infection is generally mild.

Oseltamivir (Tamiflu, Roche) for 5 days at a dose of
75 mg twice daily21 or zanamivir (Relenza,
GlaxoSmithKline) for 5 days at a dose of
two puffs (5 mg/puff) twice daily, for a
total daily dose of 20 mg21
None available

Virus

Respiratory syncytial virus

Coronavirus

Adenovirus
Rhinovirus
Atypical bacteria
Bordetella pertussis

Mycoplasma pneumoniae

Chlamydophila pneumoniae

Incubation period is 1–3 wk. Primarily affects adolescents and young adults. In some series, 10 to
20% of patients have cough with a duration of
>2 wk.13 Whooping occurs in a minority of patients.19 Fever is uncommon. A marked leukocytosis with lymphocytic predominance can occur.

Incubation period is 2–3 wk. Gradual onset (2–3
days) distinguishes this infection from influenza. Clusters occur among military recruits and
students in boarding schools.
Incubation period is 3 wk. Onset of symptoms,
which include hoarseness before cough, is gradual. Clusters reported among military recruits,
college students, and patients in nursing homes.

None available

None available

None available
None available
Macrolides as first-line therapy25:
Azithromycin (Zithromax, Pfizer) for 5 days at
a dose of 500 mg on day 1 and 250 mg on
days 2–5 or
Erythromycin (Ery-Tab, Abbott) for 14 days at
a dose of 500 mg 4 times daily or
Clarithromycin (Biaxin, Abbott) for 7 days at
a dose of 500 mg twice daily
Second-line therapy25:
Trimethoprim–sulfamethoxazole (Bactrim,
Roche) for 14 days at a dose of 1600 mg
once daily or 800 mg twice daily
Azithromycin for 5 days at a dose of 500 mg on
day 1 and 250 mg on days 2–5 or doxycycline (Vibramycin, Pfizer) for 5 days at a
dose of 100 mg twice daily or no therapy‡
Azithromycin for 5 days at a dose of 500 mg on
day 1 and 250 mg on days 2–5 or doxycycline for 5 days at a dose of 100 mg twice
daily or no therapy‡

* The cause of many cases remains uncertain. The presence or absence of a community epidemic, the time of year, the population affected,
and influenza immunization status are important risk factors for specific pathogens. Viruses generally have an incubation period of 2 to
7 days, whereas the three atypical bacteria have longer incubation periods. Such information may be helpful if the interval after contact with
ill persons is known. A gradual onset of symptoms (2 to 3 days) is more characteristic of bacterial causes than of most viral causes.
† Diagnostic testing is most useful for identifying treatable causes when an infectious agent is circulating in the community and for identifying a cause in an outbreak.
‡ There are no compelling data suggestive of improved outcomes of acute bronchitis as a result of treatment with antibiotic agents.

duration in an adolescent or young adult; fever is
less common in pertussis than in viral bronchitis.18,26 However, in the absence of an epidemic,
the positive predictive value of young age, prolonged cough, or the absence of fever is low for
pertussis. During an epidemic of influenza, the
finding of both cough and fever was reported to
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have a positive predictive value of 79% for this
condition.27
Diagnostic Testing

At the bedside, cough in the absence of fever, tachycardia, and tachypnea suggests bronchitis, rather
than pneumonia. In fact, the presence of normal
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vital signs and the absence of rales and egophony
on chest examination minimize the likelihood of
pneumonia to the point at which further diagnostic testing is usually unnecessary.28 An exception,
however, is cough in elderly patients; pneumonia
in elderly patients is often characterized by an absence of distinctive signs and symptoms. Among
patients 75 years of age or older who had community-acquired pneumonia, only 30% had a temperature above 38°C, and only 37% had a heart rate of
more than 100 beats per minute.29
Rapid diagnostic tests exist for several pathogens currently linked to acute bronchitis. However,
not all the rapid tests are widely available, and
their routine use is not cost-effective in an outpatient setting. Rapid tests should be used primarily
when the suspected organism is treatable, the infection is known to be circulating in the community, and the patient has suggestive symptoms or
signs (e.g., testing for influenza during influenza
season in patients with cough and fever) (Table 1).
Multiplex polymerase-chain-reaction (PCR) testing
of nasopharyngeal swabs or aspirates is being
developed to diagnose infections resulting from
B. pertussis, M. pneumoniae, or C. pneumoniae with
clinically useful sensitivity and specificity, as compared with culture or monoplex PCR.30

of
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showed a significant but minor reduction in the
duration of cough (0.6 day).33 There was a nonsignificant reduction in the number of days of feeling ill and a nonsignificant increase in adverse
events attributed to antibiotics (relative risk of
adverse events, 1.22; 95% confidence interval, 0.94
to 1.58).
Antimicrobial therapy may be more beneficial
when a treatable pathogen is identified than when
a treatable pathogen is not identified. For example, anti-influenza agents (including oseltamivir
and zanamivir) decrease the duration of symptoms
by approximately 1 day and result in an earlier
return to normal activity (by 0.5 day) among patients with infections caused by susceptible viruses. Prompt antibiotic treatment of patients with
pertussis is indicated to limit transmission, but
(with the possible exception of therapy initiated
during the first week of symptoms) there are no
compelling data to support the prospect that
cough will be less severe or less prolonged with
antibiotic therapy. Similarly, although several classes of antibiotics have in vitro activity against
M. pneumoniae and C. pneumoniae, it is unclear
whether antibiotic treatment of bronchitis linked
to these organisms influences outcomes. Table 1
includes suggested antimicrobial therapy for
cases in which such therapy is considered.

Treatment

2128

Antimicrobial Therapy

Other Therapy

Antimicrobial agents are not recommended in most
cases of acute bronchitis. Systematic analyses of
clinical trials have suggested that antibiotics may
reduce the duration of symptoms, but at best modestly. Specifically, a meta-analysis of eight trials
involving patients with acute bronchitis suggested that symptoms were reduced by a fraction a day
with the use of erythromycin, doxycycline, or trimethoprim–sulfamethoxazole. The results were
statistically significant but clinically trivial.31 Results of a randomized, double-blind trial comparing a 5-day course of azithromycin in 112 patients with vitamin C in 108 patients (total dose of
each agent, 1.5 g), published after the meta-analysis had been completed, showed no difference
between groups in the health-related quality of
life at 7 days (the primary outcome) or in the proportion of patients who returned to work, school,
or usual activities at home on day 3 or 7.32
A Cochrane Review of nine randomized, controlled trials of antibiotic agents (including three
trials not included in the previous review31) also

The few randomized, placebo-controlled trials that
have examined the effect of β2-agonists administered orally or by aerosol for cough associated with
acute bronchitis have involved small numbers of
patients and have had mixed results.34-36 In these
studies, among patients without preexisting lung
disease, daily cough scores and the likelihood of
persistent cough after 7 days did not differ significantly between the active treatment and placebo
groups. However, in one trial, a subgroup of patients with evidence of airflow limitation had significantly lower scores for symptoms on day 2 after
treatment with β2-agonists.34 A recent Cochrane
Review of five trials involving 418 adults showed
that even among patients with airflow obstruction,
the potential benefit of β2-agonists is not well
supported and should be balanced against the adverse effects of treatment.37 In practice, a brief trial
(7 days) of inhaled or oral corticosteroids may be
reasonable for troublesome cough (i.e., cough persisting for more than 20 days), but there are no
clinical trial data to support this approach. Data
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from clinical trials are also not available to support are only occasionally useful, and there is no routhe use of mucolytic or antitussive agents.
tine role for inhaled bronchodilators or mucolytic agents.43 However, these guidelines note that
subgroups of patients with chronic airflow obA r e a s of Uncer ta in t y
struction at baseline or wheezing at the onset of
Distinguishing the minority of cases of acute bron- illness do have a benefit from β2-agonists. Inchitis due to a treatable cause from those due to haled anticholinergic agents are not recommended.
currently nontreatable viruses is often challeng- These guidelines have been criticized on the
ing. Recently, the measurement of serum levels of grounds that many of the recommendations were
procalcitonin, which is typically elevated in bacte- based “more on opinion than on evidence.”44
rial infections, has been proposed as a means of
Both the ACCP guidelines and guidelines of the
identifying patients in whom treatment with an- Centers for Disease Control and Prevention (CDC)
tibiotics is warranted. In one clinical trial, low lev- recommend macrolides as first-line therapy for
els of procalcitonin (<0.1 μg per liter) were used pertussis.25,43 For infection with influenza A virus,
to discriminate safely between patients with cough in January 2006 the CDC recommended therapy
or dyspnea who did not require antibiotic therapy, with either oseltamivir or zanamivir,21 noting that
such as those with acute bronchitis,38 and patients the circulating H3N2 strains of influenza A virus
who did require such therapy. However, more data were almost uniformly resistant to both first-genare needed to validate the usefulness of the pro- eration drugs (amantadine and rimantadine).
calcitonin test for discriminating between patients
with bronchitis and those with pneumonia.
Sum m a r y a nd R ec om mendat ions
Although clinicians might argue that the pressure of time influences the prescribing of antibi- The patient described in the vignette most likely
otics, the data do not support this contention. has a viral infection causing uncomplicated acute
A recent study involving almost 4000 adults with bronchitis. On the basis of data from clinical
upper respiratory tract infections showed that the trials, antibacterial agents are not recommended.
mean duration of an office visit was 14.2 minutes Chest radiography is not indicated, given the abwhen antibiotics were prescribed, as compared sence of signs of pneumonia on physical examinawith 15.2 minutes when no prescription for anti- tion. In the absence of an influenza outbreak in
biotics was given.39
the community, no rapid testing for viral causes
Previous studies involving volunteers exposed to should be ordered, and no antiviral therapy
rhinovirus showed that nonsteroidal drugs alone should be prescribed; influenza is especially unor in combination with antihistamines reduced the likely in a patient who is afebrile. In the absence
severity of symptoms, including cough.40 However, of a history of contact with a person with susthe effects of either drug alone or their combina- pected pertussis (or a person with a history of
tion in naturally occurring acute bronchitis have persistent cough), this diagnosis is unlikely. If
not been evaluated. Results of a single randomized paroxysms of cough developed later or if whooptrial involving 486 adults with acute bronchitis ing or post-tussive vomiting occurred, testing for
suggested a clinical benefit of an extract of the pertussis would be reasonable. The patient should
roots of Pelargonium sidoides, but the data require be advised that the cough may persist for an additional 10 to 21 days and that infrequently, it
confirmation.41
persists longer. For his wheezing and shortness of
breath with activity, clinical experience suggests
Guidel ine s
that a β2-agonist such as albuterol may provide
According to the 2001 guidelines of the Ameri- relief, although data from clinical trials are inconcan College of Physicians for the treatment of un- sistent. On the basis of clinical experience, the pacomplicated acute bronchitis, antibiotic treatment tient might be offered short-term use of codeine or
is “not recommended, regardless of duration of hydrocodone-containing preparations or inhaled
cough.”42 According to the 2006 guidelines of corticosteroids if the cough is persistent, although
the American College of Chest Physicians (ACCP) data from trials to support their use are lacking.
Dr. Wenzel reports receiving consulting fees from Pfizer and
for treating acute bronchitis, routine treatment
Replidyne and research support from Pfizer. No other potential
with antibiotics is not justified, antitussive agents conflict of interest relevant to this article was reported.
n engl j med 355;20
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